-
Mashup Score: 2SANO-trial: neoadjuvant chemoradiotherapy vs. active Surveillance in esophageal cancer - 11 day(s) ago
Magnus Nilsson, MD, PhD, FACS, Karolinska University Hospital, Stockholm, Sweden, discusses findings from the Phase III SANO-trial (NTR6803 8-11-2017) a noni…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
4000 Background: Nivolumab plus chemotherapy (N+C) in the first-line treatment and nivolumab monotherapy in the third- or later-line have shown survival benefit in patients with unresectable advanced or recurrent G/GEJ cancer. Adjuvant chemotherapy after D2 or more extended gastrectomy is a widely used standard of care for pStage III G/GEJ cancer in Asia. However, standard adjuvant chemotherapy has shown limited efficacy for pStage III G/GEJ cancer. ATTRACTION-5 is the first phase 3 study to evaluate an immune checkpoint inhibitor in combination with adjuvant chemotherapy for pStage III G/GEJ cancer. Here, we report the first confirmatory results of N+C as postoperative adjuvant treatment. Methods: The ATTRACTION-5 study is a multicenter, double-blind, randomized study conducted in Japan, Korea, Taiwan, and China. We enrolled patients with pStage III G/GEJ cancer who had undergone D2 or more extended gastrectomy. Investigators selected an appropriate adjuvant chemotherapy (tegafur/gime
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
FLASHBACK FORWARD #ATTRACTION05 adj nivo for LA #GEA HR RFS 0.87 NS; HR OS 0.88 NS PDL1 TPS >1% (freq 13.8%) HR RFS 0.33 PDL1 TPS <1% HR RFS 1.06 CPS-10? MSI-H? https://t.co/ANonlbFSL1 https://t.co/v0X7CFg3NS
-
-
Mashup Score: 1Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer | NEJM - 5 month(s) ago
Original Article from The New England Journal of Medicine — Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
FLASHBACK FORWARD #CM577 adj nivo after CRT->S for LA GEA/esoSCC: Adeno (freq 71%) HR DFS 0.75 SCC HR DFS 0.61 PDL1 CPS>5 (AC+SCC) (freq 55.7%) HR DFS 0.62 PDL1 CPS<5 (AC+SCC) HR DFS 0.89 Await data maturity for OS. DFS/OS by CPS-10 by AC/SCC? https://t.co/IH56sqspSO https://t.co/66EjXmZEYk
-
-
Mashup Score: 17Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer - 5 month(s) ago
This randomized clinical trial evaluates whether sintilimab plus chemotherapy vs placebo plus chemotherapy improved overall survival in patients in China with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
ORIENT-16 sintilimab anti-PD1 plus chemo first line #GEA https://t.co/1d5cB7NRhP https://t.co/PIDL9u1Ouf
-
-
Mashup Score: 17Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer - 5 month(s) ago
This randomized clinical trial evaluates whether sintilimab plus chemotherapy vs placebo plus chemotherapy improved overall survival in patients in China with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
ORIENT-16 sintilimab anti-PD1 plus chemo first line #GEA https://t.co/1d5cB7NRhP https://t.co/PIDL9u1Ouf
-
-
Mashup Score: 0Effectiveness of Immune Checkpoint Inhibitors in Advanced Esophageal Squamous Cell Carcinoma - 1 year(s) ago
This meta-analysis examines whether immunotherapy confers a survival benefit for patients with advanced esophageal squamous cell carcinoma and low expression of PD-L1.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
How do we understand 2 independent meta-analyses published the same week (Yap et al JAMA Onc 2022 N= 4752; Wu et al JCO 2022 N=2908) evaluating the same question but coming to opposite conclusions?? https://t.co/oJgjuAt20E https://t.co/Y5AsI23QJe https://t.co/WWZD48PdHe
-
-
Mashup Score: 0
In a phase II clinical trial, personalized antibodies plus molecularly targeted chemotherapy improved median overall survival and the one-year survival rate in patients with gastroesophageal adenocarcinoma relative to historical survival data.
Categories: Hem/Oncs, Latest HeadlinesTweet-
@SalemGIOncDoc @OncoAlert @ILSONDavid @GIcancerDoc https://t.co/yV1v1MyCFm
-
-
Mashup Score: 2ASCO - 2 year(s) ago
View full prescribing information for Opdivo. This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA),…
Source: m.email.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/usgCCEEDSU
-
-
Mashup Score: 2
Perioperative FLOT was active and feasible to administer, and might represent an option for patients with locally advanced, resectable gastric or gastro-eosophageal junction adenocarcinoma.
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@antonyruggeri @ILSONDavid @YJanjigianMD @LizzySmyth1 @FlorianLordick @anthonyruggeri, this is a common post-op question. This is what we know: The FLOT4 study did not alter post-op tx based on TRG. Poor response (G3 Becker) occurs in ~38% and Partial (G2) in another 18%. Regardless, FLOT x 4 more cycles was given. https://t.co/5JPLZw8rly
-
-
Mashup Score: 0
The Intergroup 0116 and the MAGIC trials changed clinical practice for resectable gastric cancer in the Western world. In these trials, overall survival improved with post-operative chemoradiotherapy (CRT) and perioperative chemotherapy (CT). Intention-to-treat analysis in the CRITICS trial of post-operative CT or post-operative CRT did not show a survival difference. The current study reports on…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@antonyruggeri @ILSONDavid @YJanjigianMD @LizzySmyth1 @FlorianLordick @AnthonyRuggeri We do know that changing to CRT did not demonstrate any improvement after neoadj ECX in CRITICS. In fact, changing to CRT was worse than more ECX. However, this is for all pts; wouldn't it be good to see outcomes explicitly only in those with poor TRG??: https://t.co/P4OCSKAdOa
-
@KrishanJethwa A good STUDY is to optimize systemic tx w RT, & salvage surgery only if necessary. But a study. Have to differentiate b/w standard care now & future goals. In SANO, we don’t know difference b/w AC & SCC nor long term consequence of delayed surgery in many. https://t.co/A1OfnE38kv